Genmab, Inc. Announces Financial Results for the First Half of 2013 and Improves 2013 Financial Guidance

Published: Aug 14, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

August 14, 2013; Copenhagen, Denmark;

Interim Report First Half 2013

• Reported positive top line results in Phase III study of ofatumumab in previously untreated chronic lymphocytic leukemia (CLL)

• Received Breakthrough Therapy Designation for daratumumab

• First half net sales of Arzerra┬« increased 40% over prior year

• Improved operating result by DKK 93 million over H1 2012

• Improved guidance and year-end cash balance

Help employers find you! Check out all the jobs and post your resume.

Back to news